SU056 is a YB-1 inhibitor that interacts with YB-1, inhibiting downstream proteins and pathways. It can induce cell-cycle arrest, apoptosis, and inhibit cell migration in ovarian cancer cells.

SU056 ( 0-10 μ M, 48 hours) inhibits the growth of OVCAR3/4/5/8, SKOV3, and ID8 cells. SU056 (1 μ M, 5-8 days) inhibits colony formation in OVCAR-8 and ID8 cells in a dose-dependent manner. SU056 (1-5 μ M, 6 hours) blocks OVCAR8, SKOV3 and ID8 cells in sub G1 phase and G1 phase phase. SU056 (0-1 μ M, 12 hours) inhibits migration of OVCAR8, SKOV3 and ID8 cells. SU056 (0-5 μ M, 24 hours) induce apoptosis of OVCAR8, SKOV3, and ID8 cells. SU056 (1-5 μ M, 12 h) inhibits the expression of YB-1, TMSB10, SUMO2, and PMSB2 proteins in OVCAR8 cells. SU056 (0.1, 0.5, and 1 μ M. 48 hours) enhances the cytotoxic effect of paclitaxel (0.1, 0.5, and 1 nM) [1].

SU056 (20 mg/kg, intraperitoneal injection) inhibits tumor growth in mice implanted with ID8 cells. SU056 (10 mg/kg, intraperitoneal injection, daily) combined with paclitaxel (5 mg/kg, weekly, intraperitoneal injection) inhibits tumor growth in immunodeficient mice implanted with ovarian cancer cells (OVCAR8), and the effect is more significant than that of single administration [1].